AstraZeneca PLC — Director's Dealing 2019

Oct 9, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Viela Bio, Inc. (VIE)
CIK: 0001734517
Period of Report: 2019-10-07

Reporting Person: ASTRAZENECA PLC (10% Owner)
Reporting Person: AstraZeneca UK LTD (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-10-07	Common Stock	C	14225324	—	Acquired	14225334	Indirect
2019-10-07	Common Stock	P	425000	$19.00	Acquired	14650334	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-10-07	Series A-1 Preferred Stock	$	C	14225324	Disposed		Common Stock (14225324)	Indirect

Footnotes

F1: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis.

F2: All of these securities are owned by AstraZeneca UK Limited, which is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the shares held by AstraZeneca UK Limited, but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any.

F3: Reflects shares purchased in the Issuer's initial public offering.

F4: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering.

F5: Not applicable.